On March 23, 2026 Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, reported that the United States Patent and Trademark Office (USPTO) has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The granted patent includes claims covering methods of treating neoplastic diseases, including acute myeloid leukemia (AML), using combinations comprising iadademstat and other therapeutic agents, notably including venetoclax, a backbone therapy in the current standard of care for first-line acute myeloid leukemia.
The patent is expected to expire in January 2039, including 681 days of patent term adjustment (PTA) granted by the USPTO to compensate for delays during patent prosecution. This does not include any potential patent term extension related to regulatory review, which could further extend the patent term.
Iadademstat is currently being evaluated in seven ongoing oncology clinical trials, including the Phase Ib ALICE-2 study in first-line AML in combination with venetoclax and azacitidine. Highly encouraging preliminary data from this trial were presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) 2025 Annual Meeting, showing a 100% overall response rate (ORR) and a 90% strict complete remission (CR) rate. The trial continues to enroll rapidly, and updated data from approximately 15-16 patients (around 75% of the planned enrollment), are expected to be presented at the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress (EHA) (Free EHA Whitepaper) in June 2026.
"This U.S. patent grant represents a significant addition to our growing IP portfolio for iadademstat," said Neus Virgili, Oryzon’s Chief IP Officer. "This patent covers combinations with venetoclax, the current standard of care in first-line AML, and provides protection extending into 2039, strengthening the long-term value of our clinical programs."
In addition to this U.S. patent, Oryzon has obtained patent protection for combinations of iadademstat with venetoclax, or their use in the treatment of cancer, in Australia, Brazil, Canada, Europe, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, and Russia. Additional patent applications are pending in other jurisdictions. Oryzon also holds granted patents covering combinations of iadademstat with other AML therapies, including azacitidine and decitabine, in the United States and other countries.
(Press release, Oryzon, MAR 23, 2026, View Source [SID1234663852])